The Lyme disease market is experiencing future growth with the best players

Lyme disease is an infectious disease caused by the bacterium Borrelia burgdorferi, transmitted to humans by infected adult tick bites. Most human infections are caused by nymph bites (immature ticks). Ticks can attach to any part of the human body and transmit the infection if they are attached to the host body for 36 to 48 hours. Blacklegged ticks are responsible for the spread of Lyme disease in the northeastern, central Atlantic, and northeastern United States. However, western blacklegged ticks spread Lyme disease in areas along the Pacific coast. These regions should therefore experience rapid growth in the Lyme disease market in the near future.

The main players in the Lyme disease treatment market include Lupine Ltd., Mylan N.V., Sun Pharmaceuticals Industries Ltd., Pfizer Inc., G & W Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, GlaxoSmithKline plc. And Hospira Inc.

Request a copy of this research report: https://www.coherentmarketinsights.com/insight/request-sample/862

Fever, headache, chills, fatigue, muscle and joint pain, swollen lymph nodes and characteristic rashes (erythema migrans) are the first symptoms of Lyme disease. According to the Centers for Disease Control and Prevention (CDC), erythema migrans affects about 70% to 80% of infected people worldwide. However, untreated Lyme disease can aggravate discomfort, including intermittent pain in muscles, tendons, joints and bones, as well as severe headache, stiff neck, arthritis with joint pain. severe, irregular heartbeat, nerve pain and inflammation of the brain and spinal cord.

Lyme carditis is a rare complication of Lyme disease, which occurs when the infection invades cardiac tissues. This can interfere with normal heart rhythm, resulting in mild, moderate or severe heart block. Patients may experience palpitations, dizziness, unconsciousness, chest pain, and dyspnea. According to national surveillance data, established by the National Notifiable Disease Surveillance System (NNDSS), between 2001 and 2010, Lyme Carditis affected approximately 1% of patients with Lyme disease; preferably ceftriaxone. However, some patients may require the implantation of a temporary or permanent pacemaker, depending on the severity of the infection.

Antibiotics have proven to be the most effective treatment for Lyme disease. Patients in the early stages of Lyme disease recover quickly and completely with appropriate antibiotics such as doxycycline, amoxicillin and cefuroxime axetil. Patients with certain neurological or cardiac diseases can be treated with ceftriaxone intravenously. Patients with chronic symptoms of Lyme disease for more than 6 months can recover within a few weeks with oral antibiotic therapy.

According to the International Lyme Society and Associated Diseases (ILADS), Lyme disease is often difficult to diagnose and treat, resulting in persistent infections. ILADS recommends personalized treatment based on the severity of the symptoms, tick-borne co-infections and the patient's response to treatment. However, no antibiotic or combination of antibiotics seems to be able to eliminate Lyme disease infection. Therefore, prevalent prevalence of Lyme disease cases and the wide potential for development of the ideal antibiotic for treatment should energize the market for Lyme disease treatment in the near future.

However, prolonged exposure to antibiotics could eventually erase the beneficial intestinal flora, resulting in various health problems. This, in turn, should be a threat to the growth of the Lyme disease market. Click to read more about the Lyme Disease Treatment Market